Literature DB >> 12116014

Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique.

Anna Roca1, Fatima Abacassamo, Mari-Paz Loscertales, Llorenç Quintó, Xavier Gómez-Olivé, Fiona Fenwick, Juan Carlos Saiz, Geoffrey Toms, Pedro L Alonso.   

Abstract

A case control study was carried out in Manhiça (Mozambique). Serum samples were collected from infants < 1 year of age in hospital to assess the effect of serum antibodies on the incidence of respiratory syncytial virus (RSV) infection. Sera were collected from a total of 31 cases of RSV infection and paired uninfected controls matched for age and sex. Anti-RSV antibodies were assessed by a membrane fluorescent antibody test (MFAT) for immunoglobulin G (IgG) antibodies and by a neutralizing antibody test. IgG RSV antibodies were of higher prevalence and at higher levels in the control group when compared to the infected case group (P < 0.001), indicating an important role for IgG antibodies in protection. To assess infection before recruitment, IgA RSV antibodies were also measured by MFAT. IgA RSV antibody prevalence was very low in patients and controls (0/31 and 4/31 respectively), suggesting that most of the detected IgG RSV antibody in both groups was of maternal origin. Re-analysis of data from the subset of 27 matched, IgA RSV antibody negative infant pairs mirrored the full analysis indicating that maternal antibody has an important role in RSV protection. Similar results were obtained when neutralizing antibodies were measured and when the measurement was done against subgroup A virus strain A2, subgroup B virus strain 8/60 and a contemporary subgroup A isolate, Moz00. No significant differences in the reactivity of maternal antibodies with the three virus strains were observed. The data described below represent the first analysis of the role of maternal antibodies in reducing the risk of pediatric infection in developing countries. The results reinforce the concept of maternal vaccination for the control of RSV in very young children in whom the risk and severity of infection are the highest. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12116014     DOI: 10.1002/jmv.10148

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  20 in total

1.  Evaluation of IgG Antibodies Against Respiratory Syncytial Virus (RSV), and Associated Risk Factors for Severe Respiratory Tract Infections in Pre-School Children in North-Central, Nigeria.

Authors:  Adedayo Faneye; Babatunde O Motayo; Adeyinka Adesanmi; Bernard Onoja
Journal:  Afr J Infect Dis       Date:  2014

2.  Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus.

Authors:  Trevor R F Smith; Katherine Schultheis; Matthew P Morrow; Kimberly A Kraynyak; Jay R McCoy; Kevin C Yim; Karuppiah Muthumani; Laurent Humeau; David B Weiner; Niranjan Y Sardesai; Kate E Broderick
Journal:  Vaccine       Date:  2017-04-14       Impact factor: 3.641

3.  Virus-Specific Antibody, Viral Load, and Disease Severity in Respiratory Syncytial Virus Infection.

Authors:  Edward E Walsh; Lu Wang; Ann R Falsey; Xing Qiu; Anthony Corbett; Jeanne Holden-Wiltse; Thomas J Mariani; David J Topham; Mary T Caserta
Journal:  J Infect Dis       Date:  2018-06-20       Impact factor: 5.226

4.  Seroprevalence of respiratory syncytial virus IgG among healthy young adults in basic training for the Republic of Korea Air Force.

Authors:  Won-Ju Park
Journal:  J Korean Med Sci       Date:  2014-09-02       Impact factor: 2.153

Review 5.  Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.

Authors:  Prasad S Kulkarni; Julia L Hurwitz; Eric A F Simões; Pedro A Piedra
Journal:  Viral Immunol       Date:  2018-01-16       Impact factor: 2.257

Review 6.  Respiratory syncytial virus--a comprehensive review.

Authors:  Andrea T Borchers; Christopher Chang; M Eric Gershwin; Laurel J Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-12       Impact factor: 8.667

7.  Inflammatory responses to acute pneumovirus infection in neonatal mice.

Authors:  Cynthia A Bonville; Catherine Ptaschinski; Caroline M Percopo; Helene F Rosenberg; Joseph B Domachowske
Journal:  Virol J       Date:  2010-11-15       Impact factor: 4.099

Review 8.  An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children.

Authors:  Harish Nair; Vasundhara R Verma; Evropi Theodoratou; Lina Zgaga; Tanvir Huda; Eric A F Simões; Peter F Wright; Igor Rudan; Harry Campbell
Journal:  BMC Public Health       Date:  2011-04-13       Impact factor: 3.295

9.  The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya.

Authors:  Rachel Ochola; Charles Sande; Gregory Fegan; Paul D Scott; Graham F Medley; Patricia A Cane; D James Nokes
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

10.  Prospective clinical and serological follow-up in early childhood reveals a high rate of subclinical RSV infection and a relatively high reinfection rate within the first 3 years of life.

Authors:  A Kutsaya; T Teros-Jaakkola; L Kakkola; L Toivonen; V Peltola; M Waris; I Julkunen
Journal:  Epidemiol Infect       Date:  2016-01-06       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.